Literature DB >> 7599450

Cost-effectiveness of fracture prevention in established osteoporosis.

B Jönsson1, C Christiansen, O Johnell, J Hedbrandt.   

Abstract

This study presents the results of a computer simulation model for calculating the cost-effectiveness and cost-utility of treating patients with established osteoporosis in order to reduce the risk of fractures. The results are based on Swedish data for risk of fracture and costs. The treatment intervention modelled is based on treatment of a 62-year-old woman with established osteoporosis. The cost per hip fracture avoided is 350,000 SEK, assuming a 50% reduction in the risk of fracture due to 5 years of treatment. A sensitivity analysis for changes in the cost and effectiveness of treatment, the risk of fracture and the discount rate is performed. The cost per life-year gained and the cost per quality-adjusted life-year (QALY) gained is presented to enable comparison of the cost-effectiveness of treating osteoporosis with that of other health care interventions. A comparison between treating the same woman for osteoporosis and mild hypertension shows a cost per life-year gained of 220,000 SEK and 128,000 SEK respectively. Cost per QALY gained is very similar for the two interventions: 105,000 SEK and 103,000 SEK respectively. This model provides a tool to enable clinicians, administrators and health policy makers to analyze and understand the economic aspects of a major health policy issue.

Entities:  

Mesh:

Year:  1995        PMID: 7599450

Source DB:  PubMed          Journal:  Osteoporos Int        ISSN: 0937-941X            Impact factor:   4.507


  10 in total

Review 1.  Consensus development conference: diagnosis, prophylaxis, and treatment of osteoporosis.

Authors: 
Journal:  Am J Med       Date:  1993-06       Impact factor: 4.965

2.  Costs of hip fracture. Rehabilitation of 180 patients in primary health care.

Authors:  L Borgquist; G Lindelöw; K G Thorngren
Journal:  Acta Orthop Scand       Date:  1991-02

3.  Non-trauma mortality in elderly women with low bone mineral density. Study of Osteoporotic Fractures Research Group.

Authors:  W S Browner; D G Seeley; T M Vogt; S R Cummings
Journal:  Lancet       Date:  1991-08-10       Impact factor: 79.321

4.  Consequences of a hip fracture: a prospective study over 1 year.

Authors:  I Sernbo; O Johnell
Journal:  Osteoporos Int       Date:  1993-05       Impact factor: 4.507

5.  Mortality and morbidity after hip fractures.

Authors:  G S Keene; M J Parker; G A Pryor
Journal:  BMJ       Date:  1993-11-13

6.  The costs of treating hypertension in Sweden. An empirical investigation in primary health care.

Authors:  M Johannesson; L Borgquist; B Jönsson
Journal:  Scand J Prim Health Care       Date:  1991-09       Impact factor: 2.581

7.  Effect of salcatonin given intranasally on bone mass and fracture rates in established osteoporosis: a dose-response study.

Authors:  K Overgaard; M A Hansen; S B Jensen; C Christiansen
Journal:  BMJ       Date:  1992-09-05

8.  Evidence for efficacy of drugs affecting bone metabolism in preventing hip fracture.

Authors:  J A Kanis; O Johnell; B Gullberg; E Allander; G Dilşen; C Gennari; A A Lopes Vaz; G P Lyritis; G Mazzuoli; L Miravet
Journal:  BMJ       Date:  1992-11-07

9.  Postmenopausal estrogens in prevention of osteoporosis. Benefit virtually without risk if cardiovascular effects are considered.

Authors:  B E Hillner; J P Hollenberg; S G Pauker
Journal:  Am J Med       Date:  1986-06       Impact factor: 4.965

10.  Predicting various fragility fractures in women by forearm bone densitometry: a follow-up study.

Authors:  P Gärdsell; O Johnell; B E Nilsson; B Gullberg
Journal:  Calcif Tissue Int       Date:  1993-05       Impact factor: 4.333

  10 in total
  23 in total

Review 1.  Selecting a decision model for economic evaluation: a case study and review.

Authors:  J Karnon; J Brown
Journal:  Health Care Manag Sci       Date:  1998-10

Review 2.  Economic evaluations of interventions for the prevention and treatment of osteoporosis: a structured review of the literature.

Authors:  Rachael L Fleurence; Cynthia P Iglesias; David J Torgerson
Journal:  Osteoporos Int       Date:  2005-06-25       Impact factor: 4.507

3.  The cost-effectiveness of risedronate in the UK for the management of osteoporosis using the FRAX.

Authors:  F Borgström; O Ström; J Coelho; H Johansson; A Oden; E V McCloskey; J A Kanis
Journal:  Osteoporos Int       Date:  2009-06-30       Impact factor: 4.507

Review 4.  Osteoporosis and bone densitometry: does the emperor have clothes?

Authors:  B C Lentle
Journal:  CMAJ       Date:  1998-11-17       Impact factor: 8.262

Review 5.  Prevention of osteoporosis: cost-effectiveness of different pharmaceutical treatments.

Authors:  A Ankjaer-Jensen; O Johnell
Journal:  Osteoporos Int       Date:  1996       Impact factor: 4.507

6.  [Subtrochanteric femoral fractures].

Authors:  B Ulmar; S Simon; A Eschler; T Mittlmeier
Journal:  Unfallchirurg       Date:  2013-12       Impact factor: 1.000

Review 7.  Hip fracture prevention: cost-effective strategies.

Authors:  P Vestergaard; L Rejnmark; L Mosekilde
Journal:  Pharmacoeconomics       Date:  2001       Impact factor: 4.981

8.  The cost-effectiveness of strontium ranelate in the UK for the management of osteoporosis.

Authors:  F Borgström; O Ström; J Coelho; H Johansson; A Oden; E McCloskey; J A Kanis
Journal:  Osteoporos Int       Date:  2009-06-10       Impact factor: 4.507

9.  Intervention thresholds for osteoporosis in men and women: a study based on data from Sweden.

Authors:  John A Kanis; Olof Johnell; Anders Oden; Frederik Borgstrom; Helena Johansson; Chris De Laet; Bengt Jönsson
Journal:  Osteoporos Int       Date:  2004-04-22       Impact factor: 4.507

10.  Cost-effectiveness of universal serologic screening to prevent nontraumatic hip and vertebral fractures in patients with celiac disease.

Authors:  K T Park; Raymond Tsai; Louise Wang; Nasim Khavari; Laura Bachrach; Dorsey Bass
Journal:  Clin Gastroenterol Hepatol       Date:  2013-01-26       Impact factor: 11.382

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.